A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels
A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels. Because cancer treatment regimens are costly, they have been highly affected by the sequester cuts. ACCC Buzz reports:
After a recent hearing by the House Energy and Commerce Health Subcommittee, the Cancer Patient Protection Act of 2013 (HR 1416) is gaining support. The bi-partisan bill was introduced by Congresswoman Renee Ellmers and now enjoys 97 co-sponsors.
Our fight is not over, however. ACCC continues to educate other members of the House about the importance of this legislation. ACCC recently met with Representative Erik Paulsen’s office, who is one of the latest members to sign onto HR 1416. We are continuing to work to identify a champion in the Senate.
Read the full story here: http://bit.ly/15mNCLo
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More